This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
M. M. Budge , C. A. De Jager , E. Hogervorst , A. D. Smith and Oxford Project to Investigate Memory and Ageing (Optima) (2002). Total plasma homocysteine, age, systolic blood pressure, and cognitive performance in older people. Journal of the American Geriatrics Society, 50, 2014–2018.
R. Clarke , A. D. Smith , K. A. Jobst , H. Refsum , L. Sutton and P. M. Ueland (1998). Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Archives of Neurology, 55, 1449–1455.
J. Durga (2007). Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet, 369, 208–216.
M. F. Elias (2005). Homocysteine and cognitive performance in the Framingham Offspring Study: age is important. American Journal of Epidemiology, 162, 644–653.
M. Folstein , S. Folstein and P. McHugh (1975). “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinican. Journal of Psychiatric Research, 12, 189–198.
A. H. Ford (2010). Vitamins B(12), B(6), and folic acid for cognition in older men. Neurology, 75, 1540–1547.
A. Garcia , Y. Haron , K. Pulman , L. Hua and M. Freedman (2004). Increases in homocysteine are related to worsening of stroop scores in healthy elderly persons: a prospective follow-up study. Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 59, 1323–1327.
L. Hansson (1999). Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Pressure, 8, 177–183.
Homocysteine Studies Collaboration (2002). Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA, 288, 2015–2022.
B. Hooshmand (2010). Homocysteine and holotranscobalamin and the risk of Alzheimer Disease: a longitudinal study. Neurology, 75, 1408–1414.
D. M. Kado (2005). Homocysteine versus the vitamins folate, B6 and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Amercian Journal of Medicine, 118, 161–167.
S. Kalmijn , L. J. Launer , J. Lindemans , M. L. Bots , A. Hofman and M. M. Breteler (1999). Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. The American Journal of Epidemiology, 150, 283–289.
S. Lonati (2004). Analytical performance and method comparison study of the total homocysteine fluorescence polarization immunoassay (FPIA) on the AxSYM analyzer. Clinical Chemistry and Laboratory Medicine, 42, 228–234.
A. McCaddon and B. Regland (2006). Homocysteine and cognition: no longer a hypothesis? Medical Hypotheses, 66, 682–683.
P. Muda (2005). Effect of antihypertensive treatment with candesartan or amlodipine on glutathione and its redox status, homocysteine and vitamin concentrations in patients with essential hypertension. Journal of Hypertension, 23, 105–112.
H. E. Nelson and A. O'Connell (1978). Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex, 14, 234–244.
E. Nurk (2005). Plasma total homocysteine and memory in the elderly: the Hordaland Homocysteine Study. Annals of Neurology, 58, 847–857.
ONTARGET Investigators (2008). Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine, 358, 1547–1559. doi: 10.1056/NEJMoa0801317.
N. D. Prins (2002). Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology, 59, 1375–1380.
R. Reitan (1958). Validity of the trailmaking test as an indicator of organic brain damage. Perceptual Motor Skills, 8, 271–276.
B. K. Saxby , F. Harrington , I. G. Mckeith , K. A. Wesnes and G. A. Ford (2003). Effects of hypertension on attention, memory, and executive function in older adults. Health Psychology, 22, 587–591.
B. K. Saxby , F. Harrington , K. A. Wesnes , I. G. Mckeith and G. A. Ford (2008). Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology, 70, 1858–1866.
J. H. Schafer , T. A. Glass , K. I. Bolla , M. Mintz , A. E. Jedlicka and B. S. Schwartz (2005). Homocysteine and cognitive function in a population-based study of older adults. Journal of the American Geriatrics Society, 53, 381–388.
S. Seshadri (2002). Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. New England Journal of Medicine, 346, 476–483.
P. Simpson , D. Surmon , K. A. Wesnes and G. Wilcock (1991). The Cognitive Drug Research computerized assessment system for demented patients: a validation study. International Journal of Geriatric Psychiatry, 6, 95–102.
A. D. Smith (2010). Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS ONE, 5, e12244. doi: 10.1371/journal.pone.0012244.
A. M. Troen (2005). The central nervous system in animal models in hyperhomocysteinemia. Progress in Neuro-Pyschopharmacology and Biological Psychiatry, 29, 1140–1151.
F. van Dam and W. A. van Gool (2009). Hyperhomocysteinemia and Alzheimer's disease: a systematic review. Archives of Gerontology and Geriatrics, 48, 425–430.